We are analyzing https://link.springer.com/article/10.1007/s40265-019-1057-0.

Title:
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity | Drugs
Description:
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductions in body weight and adiposity. The ability to reduce body weight is consistently observed in individuals taking SGLT2 inhibitors, but this weight loss is moderate due to counter-regulatory mechanisms striving to maintain body weight. This has prompted exploration of SGLT2 inhibitors in combination with other agents acting via decreased food intake, e.g., glucagon-like peptide 1 receptor agonists (GLP1-RAs). The bodyweight effects are promising, and together with the signs of prevention of cardiovascular and renal events, such combinations including SGLT2 inhibitors are appealing. The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Fitness & Wellness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

diabetes, pubmed, sglt, article, google, scholar, inhibitors, cas, weight, type, patients, loss, dapagliflozin, obese, effects, combination, obesity, glucose, therapy, treatment, body, cardiovascular, study, metab, subjects, inhibitor, trial, central, obes, renal, metformin, insulin, blood, efficacy, reduction, monotherapy, studies, controlled, safety, randomized, canagliflozin, pressure, individuals, bodyweight, clinical, med, reduce, intake, week, nct,

Topics {✒️}

int/mediacentre/factsheets/fs311/en/ article download pdf uncontrolled open-label extension long-term weight maintenance counter-regulatory mechanisms striving physiological counter-regulatory mechanisms long-term trials designed active-controlled noninferiority trial short-term weight loss peptide-1-induced insulin secretion address counter-regulatory mechanisms long-term cardiovascular events long-term glycaemic response post-meal glucagon concentrations diet-induced obese mice empa-reg outcome study low-grade chronic inflammation additional glucose-lowering therapies selective sodium-glucose drug-naive asian patients total fat mass growing health issue placebo-controlled 102-week trial reduce arterial stiffness bailey cj privacy choices/manage cookies ly3298176 glp1 + gip-ra [78] effective weight-loss therapies mearns es body fat mass randomized double-blind trial frias jp weight loss induced endocrinology position statement regulate endogenous production glomerular filtration rate blood glucose levels wiviott sd fat mass reduction empa-reg outcome diet-induced obese metformin-based combination therapy leibel rl glp-1 receptor agonist gerich je peptide-1 receptor agonists real world analysis plasma glucose concentration plasma glucose drops meta-analyses show

Questions {❓}

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study?
Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
         description:Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductions in body weight and adiposity. The ability to reduce body weight is consistently observed in individuals taking SGLT2 inhibitors, but this weight loss is moderate due to counter-regulatory mechanisms striving to maintain body weight. This has prompted exploration of SGLT2 inhibitors in combination with other agents acting via decreased food intake, e.g., glucagon-like peptide 1 receptor agonists (GLP1-RAs). The bodyweight effects are promising, and together with the signs of prevention of cardiovascular and renal events, such combinations including SGLT2 inhibitors are appealing. The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes.
         datePublished:2019-01-30T00:00:00Z
         dateModified:2019-01-30T00:00:00Z
         pageStart:219
         pageEnd:230
         sameAs:https://doi.org/10.1007/s40265-019-1057-0
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-1057-0/MediaObjects/40265_2019_1057_Fig1_HTML.png
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:79
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Maria J. Pereira
               affiliation:
                     name:Uppsala University
                     address:
                        name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jan W. Eriksson
               affiliation:
                     name:Uppsala University
                     address:
                        name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
      description:Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductions in body weight and adiposity. The ability to reduce body weight is consistently observed in individuals taking SGLT2 inhibitors, but this weight loss is moderate due to counter-regulatory mechanisms striving to maintain body weight. This has prompted exploration of SGLT2 inhibitors in combination with other agents acting via decreased food intake, e.g., glucagon-like peptide 1 receptor agonists (GLP1-RAs). The bodyweight effects are promising, and together with the signs of prevention of cardiovascular and renal events, such combinations including SGLT2 inhibitors are appealing. The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes.
      datePublished:2019-01-30T00:00:00Z
      dateModified:2019-01-30T00:00:00Z
      pageStart:219
      pageEnd:230
      sameAs:https://doi.org/10.1007/s40265-019-1057-0
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-019-1057-0/MediaObjects/40265_2019_1057_Fig1_HTML.png
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:79
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Maria J. Pereira
            affiliation:
                  name:Uppsala University
                  address:
                     name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jan W. Eriksson
            affiliation:
                  name:Uppsala University
                  address:
                     name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:79
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Uppsala University
      address:
         name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
         type:PostalAddress
      name:Uppsala University
      address:
         name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Maria J. Pereira
      affiliation:
            name:Uppsala University
            address:
               name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
               type:PostalAddress
            type:Organization
      name:Jan W. Eriksson
      affiliation:
            name:Uppsala University
            address:
               name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden
      name:Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden

External Links {🔗}(318)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.59s.

LINK . SPRINGER . COM {}